Compact quantitative near infrared device for combat casualty care

Award Information
Agency:
Department of Defense
Amount:
$70,000.00
Program:
SBIR
Contract:
W81XWH-09-C-0006
Solitcitation Year:
2008
Solicitation Number:
2008.2
Branch:
Army
Award Year:
2008
Phase:
Phase I
Agency Tracking Number:
A082-119-1445
Solicitation Topic Code:
A08-119
Small Business Information
ISS, INC.
1602 Newton Drive, Champaign, IL, 61822
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
152117347
Principal Investigator
 Dennis Hueber
 Director of Engineering
 (217) 359-8681
 dennis.hueber@iss.com
Business Contact
 Beniamino Barbieri
Title: President
Phone: (217) 359-8681
Email: bb@iss.com
Research Institution
N/A
Abstract
The early recognition of severe hemorrhage is a key factor towards reducing mortality and morbidity from battlefield insults. Although near-infrared (NIR) instruments have shown promise in recognizing hemorrhage, specific confounding factors must be solved to be reliable in early hemorrhage. Our hypothesis is that these confounding factors can be eliminated by proper light-tissue interaction modeling (frequency-domain photon migration), and by increasing spectral (1000 wavelengths) and temporal (200 ms) bandwidth. The objective of this proposal is to provide a compact point-of-care NIR instrument that is capable of quantitatively detecting early hemorrhage and monitoring therapeutic interventions. Our proposal features collaboration between (1) a leading biomedical technology company (ISS, Inc., Champaign, IL) that produces state-of-the-art NIR tissue oximeters, operates production facilities and has FDA submission experience, and (2) a university research team (Beckman Laser Institute, UC Irvine), with tissue optics experts who have experience in the assessment of traumatic injury via NIR optical methods. The existing ISS oximeter will be modified to increase information content that will solve the confounding factors. At the conclusion of Phase I, we will provide a unique NIR instrument that will be available for comprehensive validation and optimization studies (Phase II) and subsequent commercial miniaturization (Phase III).

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government